[ad_1]
Professor Seok-Ah Lim of Seoul National University Hospital “New Treatment Options for Young Breast Cancer Patients”
[현대건강신문=여혜숙 기자] New treatments have emerged to prolong the survival of young patients with breast cancer before menopause.Breast cancer is the number one cancer incidence rate among female cancer in Korea, and the 5-year relative survival rate continues to rise to 93.2%. However, not all patients have good results. When diagnosed with advanced or metastatic breast cancer, the 5-year relative survival rate drops to 27%.
In particular, premenopausal breast cancer is known to have a poor treatment outcome and a poor prognosis compared to postmenopausal breast cancer.
In Korea, the rate of premenopausal breast cancer is significantly higher than in the West. About 10.5% of premenopausal breast cancer patients younger than 40 years are 2 times taller than Western patients. As such, patients with metastatic breast cancer in Korea need a new treatment option to eliminate blind spots.
Among these, KiscaliTM from Novartis Korea (ingredient name: ribociclib) is the only CDK4 / 6 inhibitor among menopausal patients that demonstrates overall survival in two phase 3 clinical trials, thus providing new treatment opportunities for young patients with breast cancer He was able to provide.
Positive premenopausal hormone (HR) / Human epithelial cell growth factor receptor 2 (HER2) Negative progression and metastatic breast cancer focused on the MONALEESA-7 study by Keith Carly, the only clinical trial focused on premenopausal breast cancer Continued
In particular, it is significant that approximately 30% of all patients participating in the clinical trials were Asian patients, including domestic patients, who demonstrated the extent of their overall survival.
Professor Seok-Ah Lim (Seoul National University Hospital Hematology and Oncology Hospital), one of the leading authors and researchers led by a Korean researcher, introduced Kiscali as a new treatment option for young patients with breast cancer .
Professor Lim said, “MONALEESA-7 is a clinical study led and initiated by Asian researchers. In this study, approximately 30% of all Asian patients were enrolled in this study. It reflects the fact that it was great.”
“With low interest in new treatment options, so few clinical studies focused on advanced and metastatic premenopausal breast cancer have been in progress for the past 20 years, MONALEESA-7 replaces invasive ovaryectomy with ovarian function inhibitors and scents . “It is significant because it is the only large-scale phase 3 clinical study conducted only for patients with advanced and metastatic breast cancer before menopause by adding Keith Cali to endocrine therapy in combination with a thalase inhibitor.”
Kiscali demonstrated improved overall survival while maintaining quality of life for the first time as a CDK4 / 6 inhibitor in patients with advanced and metastatic breast cancer before menopause HR + / HER2-, in a phase 3 study from MONALEESA-7.
The total survival period (OS) at 42 months of the combined Kiscali + endocrine therapy group (ovarian function inhibitors and aromatase inhibitors) was 70.2%, and that of the endocrine therapy alone group was 46 , 0%. % Reduction.
It was also confirmed that the progression-free survival (PFS) period improved compared to 13.0 months in the endocrine therapy alone group with 23.8 months in combination with Keith Cali.
Furthermore, through the MONALEESA-3 clinical study, Keith Carly confirmed the effect of extending the general survival period in postmenopausal and postmenopausal women2. At 42 months, the estimated survival rate was 58% in the Kiscali combination group and 46% in the Fulvestrant group.
Professor Im said: “It is very significant to be able to extend the survival period with new treatments for young breast cancer patients who are socially active and have someone’s wife and parents.” “We expect a higher survival rate for young breast cancer patients who lack options.”
